Literature DB >> 10753849

MUC1 is activated in a B-cell lymphoma by the t(1;14)(q21;q32) translocation and is rearranged and amplified in B-cell lymphoma subsets.

V G Dyomin1, N Palanisamy, K O Lloyd, K Dyomina, S C Jhanwar, J Houldsworth, R S Chaganti.   

Abstract

The band 1q21 is among the most common sites affected by chromosomal translocations in lymphoid, myeloid, epithelial, and sarcomatous lesions. In non-Hodgkin's lymphoma (NHL), translocations and duplications affecting this chromosomal site are frequently, but not exclusively, seen in association with primary abnormalities such as the t(14;18)(q32;q21) and t(8;14)(q24;q32) translocations, suggesting a role for 1q21 rearrangements in tumor progression. We report here the characterization and cloning of breakpoints in a case of extranodal ascitic B-cell lymphoma with a t(1;14)(q21;q32) translocation. The breakpoints on the der(1) and der(14) chromosomes were mapped by fluorescence in situ hybridization and Southern blot analysis and cloned using an IGHG (Cgamma) probe. The translocation linked the IGHG4 switch (Sgamma4) sequences of the productively rearranged allele to chromosome 1 sequences downstream of MUC1, leaving the MUC1 transcriptional unit intact. MUC1 was markedly overexpressed in the tumor at the mRNA and protein levels relative to lymphoma cell lines lacking a 1q21 rearrangement. Presumably, MUC1 transcription is aberrantly regulated by the IGHA (Calpha) 3' enhancer element retained on the same chromosome. Screening of a panel of B-cell lymphomas by Southern blot analysis identified a subset with a 3' MUC1 breakpoint and another with low-level amplification of MUC1. MUC-1 mucin has previously been shown to be frequently overexpressed in human epithelial cancers and to be associated with tumor progression and poor clinical outcome. Thus, MUC1 activation by chromosomal translocation, rearrangement, and amplification, identified here for the first time in NHL, is consistent with its suggested role in tumorigenesis. (Blood. 2000;95:2666-2671)

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10753849

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  18 in total

Review 1.  Molecular diagnostic approach to non-Hodgkin's lymphoma.

Authors:  D A Arber
Journal:  J Mol Diagn       Date:  2000-11       Impact factor: 5.568

2.  MUC1 plays a role in tumor maintenance in aggressive thyroid carcinomas.

Authors:  Kepal N Patel; Ellie Maghami; Volkert B Wreesmann; Ashok R Shaha; Jatin P Shah; Ronald Ghossein; Bhuvanesh Singh
Journal:  Surgery       Date:  2005-12       Impact factor: 3.982

3.  Aberrant expression of CD227 is correlated with tumor characteristics and invasiveness of breast carcinoma.

Authors:  Ya-Wen Wang; Duan-Bo Shi; Ya-Min Liu; Yan-Lin Sun; Xu Chen; Shuai Xiang; Qiang Fu; Jun-Min Wei; Peng Gao
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-01       Impact factor: 4.553

4.  MUC1 oncoprotein blocks death receptor-mediated apoptosis by inhibiting recruitment of caspase-8.

Authors:  Naoki Agata; Rehan Ahmad; Takeshi Kawano; Deepak Raina; Surender Kharbanda; Donald Kufe
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

Review 5.  Mucins in cancer: function, prognosis and therapy.

Authors:  Donald W Kufe
Journal:  Nat Rev Cancer       Date:  2009-12       Impact factor: 60.716

Review 6.  MUC1 in hematological malignancies.

Authors:  Dina Stroopinsky; Donald Kufe; David Avigan
Journal:  Leuk Lymphoma       Date:  2016-06-27

7.  MUC1 oncoprotein promotes growth and survival of human multiple myeloma cells.

Authors:  Takeshi Kawano; Rehan Ahmad; Hiroko Nogi; Naoki Agata; Kenneth Anderson; Donald Kufe
Journal:  Int J Oncol       Date:  2008-07       Impact factor: 5.650

8.  MUC1 oncoprotein activates the IkappaB kinase beta complex and constitutive NF-kappaB signalling.

Authors:  Rehan Ahmad; Deepak Raina; Vishal Trivedi; Jian Ren; Hasan Rajabi; Surender Kharbanda; Donald Kufe
Journal:  Nat Cell Biol       Date:  2007-11-25       Impact factor: 28.824

9.  BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells.

Authors:  Mala Mani; Daniel E Carrasco; Yunyu Zhang; Kohichi Takada; Moshe E Gatt; Jui Dutta-Simmons; Hiroshi Ikeda; Felipe Diaz-Griffero; Victor Pena-Cruz; Monica Bertagnolli; Lois L Myeroff; Sanford D Markowitz; Kenneth C Anderson; Daniel R Carrasco
Journal:  Cancer Res       Date:  2009-09-08       Impact factor: 12.701

10.  Expression of underglycosylated MUC1 antigen in cancerous and adjacent normal breast tissues.

Authors:  Subrata K Ghosh; Pamela Pantazopoulos; Zdravka Medarova; Anna Moore
Journal:  Clin Breast Cancer       Date:  2012-11-01       Impact factor: 3.225

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.